Update on recent research into infantile hemangioma.
10.5124/jkma.2016.59.9.698
- Author:
Meerim PARK
1
Author Information
1. Department of Pediatrics, Chungbuk National University College of Medicine, Cheongju, Korea. ming2a@hanmail.net
- Publication Type:Original Article
- Keywords:
Infantile hemangioma;
Propranolol;
Clinical course;
Management
- MeSH:
Adrenal Cortex Hormones;
Hemangioma*;
Humans;
Infant;
Laser Therapy;
Propranolol;
Steroids;
Vincristine
- From:Journal of the Korean Medical Association
2016;59(9):698-704
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Infantile hemangioma (IH) is the most common type of benign tumor during infancy. Due to their propensity to spontaneously involute, most IHs can be left untreated. However, IHs located in particular anatomic areas and those with complications need rapid and active treatment. It is often challenging for clinicians to predict which IHs are in need of systemic treatment. Data from various studies have revealed further insights into IH. The treatment options include propranolol, steroids, interferon-α, vincristine, surgical excision, and laser therapy. More infants are now treated with propranolol than were previously treated with oral corticosteroids, and the full implications of this shift in practice are not yet clear. This paper summarizes the pathogenesis, clinical course and current recommendations for management of IHs.
